Cytosorbents (CTSO) vs SiNtx Technologies (SINT)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
SiNtx Technologies (SINT) has outperformed Cytosorbents (CTSO) over the past year, losing 53.3% versus a loss of 80.9%. Over five years, CTSO leads with a -96.8% price change compared with -100.0% for SINT. SiNtx Technologies is the larger company by market cap ($14.1 million vs $11.3 million), about 1.2 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | CTSO | SINT |
|---|---|---|
| Share price | $3.59 | $2.12 |
| Market cap | $11.31M | $14.10M |
| 1-day change | -3.78% | +0.24% |
| YTD return | -70.81% | -45.34% |
| 1-year return | -80.87% | -53.32% |
| 5-year return | -96.82% | -99.99% |
| EPS (TTM) | $-5.80 | $-4.91 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $19.72 | $4.64 |
| 52-week low | $3.59 | $1.40 |
| Distance from 52-week high | -81.80% | -54.42% |
| Analyst consensus | none | strong_buy |
| Avg. price target upside | +1223.53% | +337.35% |
| Average volume | 12.45K | 112.93K |
| Shares outstanding | 3.15M | 6.66M |
| Employees | 129 | 32 |
| Sector | Health Care | Health Care |
| Industry | Medical/Dental Instruments | Medical/Dental Instruments |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- SINT has outperformed CTSO by 27.6 percentage points over the past year.
About Cytosorbents
CTSO stock →Cytosorbents Corporation engages in the research, development, and commercialization of medical devices with its blood purification technology platform in the United States, Germany, and internationally. Its flagship product, CytoSorb, is an extracorporeal blood purification cartridge to reduce cytokine storms in common critical illnesses, bilirubin in liver failure, myoglobin in trauma and critical illnesses, and inflammatory mediators and blood thinners in cardiac surgery applications, as well as to remove antithrombotic drugs and inflammatory mediators in cardiothoracic surgery applications.
Health Care · Medical/Dental Instruments · 129 employees
About SiNtx Technologies
SINT stock →Sintx Technologies, Inc., an advanced ceramics company, engages in the research, development, and commercialization of medical devices manufactured with silicon nitride for biomedical, technical, and antipathogenic applications in the United States. The company offers monolithic solid silicon nitride; solid and porous silicon nitride; silicon nitrite powder; and silicon nitride coating products, as well as silicon nitride composite materials, polyether ether ketone, and Polyether Ether Ketone (PEE).
Health Care · Medical/Dental Instruments · 32 employees
CTSO vs SINT FAQ
Which is bigger, Cytosorbents or SiNtx Technologies?
SiNtx Technologies (SINT) is larger, with a market capitalization of $14.10M compared with $11.31M for Cytosorbents (CTSO).
Which stock has performed better over the past year, CTSO or SINT?
SINT returned -53.32% over the past 12 months, compared with -80.87% for CTSO (price return, excluding dividends). Past performance does not predict future results.
Are Cytosorbents and SiNtx Technologies in the same industry?
Yes. Both are classified in the Medical/Dental Instruments industry within the Health Care sector.